title: Essential thrombocythemias without V617F JAK2 mutation are clonal hematopoietic stem cell disorders.
authors.forename: J-J
authors.initials: JJ
authors.lastname: Kiladjian
authors.forename: N
authors.initials: N
authors.lastname: Elkassar
authors.forename: B
authors.initials: B
authors.lastname: Cassinat
authors.forename: G
authors.initials: G
authors.lastname: Hetet
authors.forename: S
authors.initials: S
authors.lastname: Giraudier
authors.forename: N
authors.initials: N
authors.lastname: Balitrand
authors.forename: C
authors.initials: C
authors.lastname: Conejero
authors.forename: J
authors.initials: J
authors.lastname: Briere
authors.forename: P
authors.initials: P
authors.lastname: Fenaux
authors.forename: C
authors.initials: C
authors.lastname: Chomienne
authors.forename: B
authors.initials: B
authors.lastname: Grandchamp
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D002999:Clone Cells / Q000473:pathology; D005260:Female; D005500:Follow-Up Studies; D006412:Hematopoietic Stem Cells / Q000473:pathology*; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D016898:Interferon-alpha / Q000627:therapeutic use; D053614:Janus Kinase 2; D008875:Middle Aged; D009154:Mutation; D011505:Protein-Tyrosine Kinases / Q000235:genetics*; D011518:Proto-Oncogene Proteins / Q000235:genetics*; D013920:Thrombocythemia, Essential / Q000175:diagnosis / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology*; D016896:Treatment Outcome
chemical_list: D016898:Interferon-alpha; D011518:Proto-Oncogene Proteins; D011505:Protein-Tyrosine Kinases; C507924:JAK2 protein, human; D053614:Janus Kinase 2; D006918:Hydroxyurea